title: Comprehensive risk reduction in patients with atrial fibrillation: Emerging diagnostic and therapeutic options. Executive summary of the report from the 3rd AFNET/EHRA consensus conference.
abstract: There are exciting new developments in several areas of atrial fibrillation (AF) management that carry the hope of improving outcomes in AF patients. This paper is an executive summary that summarises the proceedings from the 3rd AFNET/EHRA consensus conference on atrial fibrillation, held in Sophia Antipolis from November 7th to 9th 2010, shortly after the release of the new ESC guidelines on AF. The conference was jointly organised by the German Atrial Fibrillation competence NETwork (AFNET) and the European Heart Rhythm Association (EHRA). This executive summary report covers four sections: 1. Risk factors and risk markers for AF, 2. Pathophysiological classification of AF, 3. Relevance of monitored AF duration for AF-related outcomes, and 4. Perspectives and needs for implementing better antithrombotic therapy.
authors: Hospital of University of Münster, Münster, Germany. p.kirchhof@bham.ac.uk
authors: Paulus
authors: P
authors: Kirchhof
authors: Gregory Y H
authors: GY
authors: Lip
authors: Isabelle C
authors: IC
authors: Van Gelder
authors: Jeroen
authors: J
authors: Bax
authors: Elaine
authors: E
authors: Hylek
authors: Stefan
authors: S
authors: Kääb
authors: Ulrich
authors: U
authors: Schotten
authors: Karl
authors: K
authors: Wegscheider
authors: Giuseppe
authors: G
authors: Boriani
authors: Michael
authors: M
authors: Ezekowitz
authors: Hans
authors: H
authors: Diener
authors: Hein
authors: H
authors: Heidbuchel
authors: Deirdre
authors: D
authors: Lane
authors: Luis
authors: L
authors: Mont
authors: Stephan
authors: S
authors: Willems
authors: Paul
authors: P
authors: Dorian
authors: Panos
authors: P
authors: Vardas
authors: Günter
authors: G
authors: Breithardt
authors: A John
authors: AJ
authors: Camm
mesh_terms: D001281:Atrial Fibrillation / Q000145:classification / Q000175:diagnosis* / Q000188:drug therapy* / Q000503:physiopathology; D015415:Biomarkers / Q000378:metabolism; D005060:Europe; D005343:Fibrinolytic Agents / Q000627:therapeutic use*; D006801:Humans; D017410:Practice Guidelines as Topic; D012307:Risk Factors; D040242:Risk Reduction Behavior
chemical_list: D015415:Biomarkers; D005343:Fibrinolytic Agents